EW
Edwards Lifesciences Corporation · Healthcare · Medical - Devices
Momentum inputs (comparable managers):
holder breadth +5.6% ·
share flow +29.1% ·
net new positions +5.3%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 14.87M | $1.28B | n/a | n/a |
| Q2 2026 | 163 | -6 | 423.46M | $38.23B | +2 | −9 |
| Q1 2026 | 173 | +2 | 408.99M | $32.75B | +6 | −5 |
| Q4 2025 | 170 | 0 | 441.50M | $37.63B | +2 | −1 |
| Q3 2025 | 24 | -1 | 280.60M | $21.82B | +1 | −3 |
| Q2 2025 | 23 | 0 | 232.09M | $18.15B | n/a | n/a |
| Q1 2025 | 20 | -1 | 112.98M | $8.18B | n/a | −1 |
| Q4 2024 | 21 | +1 | 116.40M | $8.61B | +1 | n/a |
| Q3 2024 | 19 | +1 | 77.58M | $5.12B | +2 | −1 |
| Q2 2024 | 18 | n/a | 60.09M | $5.55B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wellington Management ✦ | 31.53M | +86.3% | $2.08B | 0.4% | ▲ Add | 2 | SEC ↗ ×9 |
| 2 | Geode Capital Management ✦ (passive) | 13.52M | +2.1% | $889.05M | 0.1% | ▲ Add | 2 | SEC ↗ ×2 |
| 3 | Fisher Asset Management ✦ | 9.08M | +9.8% | $599.08M | 0.2% | ▲ Add | 2 | SEC ↗ |
| 4 | Norges Bank ✦ (passive) | 7.22M | -15.4% | $476.46M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 5 | Marshall Wace ✦ | 3.73M | +4900.6% | $246.39M | 0.3% | ▲ Add | 2 | SEC ↗ ×2 |
| 6 | T. Rowe Price ✦ | 3.54M | -51.7% | $233.72M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 7 | Citadel Advisors ✦ | 1.99M | +218.9% | $131.42M | 0.1% | ▲ Add | 2 | SEC ↗ ×2 |
| 8 | PRIMECAP Management ✦ | 1.78M | -1.4% | $117.77M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 9 | Renaissance Technologies ✦ | 1.22M | New | $80.62M | 0.1% | New | 1 | SEC ↗ |
| 10 | Millennium Management ✦ | 1.14M | +117.7% | $75.30M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 11 | D. E. Shaw & Co. ✦ | 983.22K | +996.7% | $64.88M | 0.1% | ▲ Add | 2 | SEC ↗ ×2 |
| 12 | Adage Capital Partners ✦ | 834.75K | +28.5% | $55.09M | 0.1% | ▲ Add | 2 | SEC ↗ |
| 13 | Soros Fund Management ✦ | 300.00K | New | $19.80M | 0.6% | New | 1 | SEC ↗ |
| 14 | Baillie Gifford ✦ | 208.70K | -40.8% | $13.77M | 0.0% | ▼ Trim | 2 | SEC ↗ ×4 |
| 15 | Bridgewater Associates ✦ | 165.45K | -68.2% | $10.92M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 145.58K | -52.9% | $9.61M | 0.0% | ▼ Trim | 2 | SEC ↗ ×3 |
| 17 | Arrowstreet Capital ✦ | 89.78K | -60.1% | $5.92M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 18 | Two Sigma Investments ✦ | 74.57K | -51.0% | $4.92M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 19 | Gotham Asset Management ✦ | 7.98K | -32.7% | $526,534 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Renaissance Technologies | $80.62M | 0.1% |
| Soros Fund Management | $19.80M | 0.6% |
Exited
| Point72 Asset Management | $41.03M | was 0.1% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 4 holders, 229.24K shares, $319,498 reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 619 sh · $53,017
Officer · 619 sh · $54,169
Officer · 544 sh · $49,534
Officer · 2.64K sh · $237,907
Officer · 1.24K sh · $113,417
Officer · 1.15K sh · $105,893
Officer · 30.65K sh · $2.79M
Officer · 619 sh · $56,967
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology